Bulletin from Egetis Therapeutics’ Annual General Meeting 2022

May 30, 2022

Stockholm, Sweden, May 30, 2022. Egetis Therapeutics AB (publ) (STO: EGTX) today announced that the Annual General Meeting (AGM) has been held on May 30, 2022, at which meeting submitted proposals were passed. The complete resolution proposals are stated in the AGM notice.

The meeting was held through postal voting in accordance with temporary legislation. Among other items of business, the following resolutions were taken:

The income statements and balance sheets were adopted, together with the Board of Directors' proposal for allocation of the company’s result. The Board of Directors and CEO were discharged from liability for the financial year 2021.

Thomas Lönngren, Mats Blom, Gunilla Osswald, Elisabeth Svanberg and Peder Walberg were re-elected as members of the Board. Thomas Lönngren was re-elected as Chairman of the Board.

The AGM voted on directors’ fees in accordance with the Nomination Committee’s proposal, i.e. that fees to the Board members and to the Chairman of the Board should be paid as follows:

It was resolved that remuneration shall be paid with SEK 600,000 for the chairman, SEK 225,000 for other board members not employed by the company and that no remuneration be paid to board members who are employed by the company. Furthermore, SEK 50,000 shall be paid to the chairman of the audit committee and SEK 25,000 to each other member of the audit committee. Finally, SEK 30,000 shall be paid to the chairman of the remuneration committee and SEK 15,000 to each other member of the remuneration committee.

It was resolved to elect the registered accounting firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. Authorized public accountant Leonard Daun will assume the role as auditor in charge.

The Nomination Committee´s proposal regarding the establishment of a Nomination Committee and Nomination Committee instructions was approved.

The remuneration guidelines for senior executives was approved by the AGM.

The AGM approved the Board of Directors’ remuneration report for 2021.

The proposed new Articles of Association were adopted. In particular, the new Articles allow the company to collect proxies in accordance with the procedure set out in the Swedish Companies Act and to resolve that shareholders shall be entitled to exercise their voting rights by post.

The AGM approved the proposal from the Board of Directors regarding the introduction of a long-term incentive program for the company’s management and key personnel.

The AGM voted, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors, to issue shares, warrants and/or convertibles.

Minutes with complete resolutions from the AGM will be made available on the company´s website, www.egetis.com

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company’s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum T3 levels and secondary clinical endpoints. As a result of fruitful regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in the first half of 2023 based on existing clinical data.
In the US, after discussions with the FDA, Egetis will conduct a small randomized, placebo-controlled study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for Emcitate in mid-2023 under the Fast-Track Designation granted by FDA.
Emcitate is currently being investigated in the fully recruited Triac Trial II, a Phase II/III study in very young MCT8 deficiency patients (<30 months of age) exploring potential disease modifying effects of early intervention from a neurocognitive and neurodevelopmental perspective. Results are expected in the first quarter of 2024 and are expected to be submitted post-approval to regulatory authorities shortly thereafter.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH- β) in the US and the EU. Emcitate has been granted Rare Pediatric Disease Designation (RPD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval.
The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study with the purpose of applying for market approval in the US and Europe for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted ODD in the US and an application for ODD was submitted in the EU in the first quarter of 2021. There is an ongoing dialogue with EMA on the appropriate scope of the indication for an ODD in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Bulletin from Egetis Therapeutics’ Annual General Meeting 2022

Contact us